Shilpa Medicare Limited — Investor Meet, 10-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Shilpa Medicare delivered strong Q1 FY27 results: revenue hit INR469 crores (+43% YoY), EBITDA INR139 crores (+42% YoY), and PAT INR101 crores (+115% YoY). Net debt-to-EBITDA improved to 1.3x, ROCE to 12.5%. Management stated major investments are complete, focusing on monetizing assets.

API revenue grew 15% (CDMO, captive demand), Formulations surged over 100% (complex FDA products), and Biologics revenue rose 42% (licensing, CDMO). Key pipeline: 3 NCE programs commercializing in FY28, Nor-UDCA global Phase II, and biosimilar launches (Aflibercept India FY27, Nivolumab India FY28). Company anticipates robust growth, leveraging integrated capabilities.